在NCI指定的4个癌症中心的患者中,大麻和阿片类药物的感知,共用和替代
Rebecca L Ashare1,2, Brooke Worster3, Shannon M Nugent4,5
1Abramson Cancer Center at the University of Pennsylvania, Philadelphia, PA, USA.
Journal of the National Cancer Institute. Monographs
|August 7, 2024
概括
与白人患者相比,患有癌症的黑人患者使用阿片类药物较少,并更喜欢大麻治疗疼痛. 社会经济因素,而不是种族,似乎推动了疼痛管理中的这些差异.
科学领域:
- 在瘤学瘤学.
- 疼痛管理 疼痛管理
- 健康差异 在健康上的差异
背景情况:
- 阿片类药物是癌症疼痛的标准,但存在获取差异.
- 大麻正在成为癌症症状管理的替代品.
- 关于癌症患者同时使用阿片类药物和大麻的数据有限.
研究的目的:
- 评估阿片类药物和大麻使用对癌症疼痛的看法和模式.
- 调查疼痛管理策略中的种族和民族差异.
- 检查大麻对阿片类药物的潜在替代.
主要方法:
- 来自NCI指定的4个癌症中心的1220名患者的调查数据.
- 感知分析,使用大麻和阿片类药物治疗疼痛,以及替代.
- 评估种族和民族差异,控制社会经济因素.
主要成果:
- 与白人患者相比,黑人患者使用阿片类药物的可能性较低 (OR=0.66) 并更有可能发现大麻比阿片类药物更有效 (OR=2.46).
- 在考虑社会经济地位后,阿片类药物和大麻使用的基于种族的差异并不显著.
- 社会经济因素似乎调解了观察到的疼痛管理中的种族差异.
结论:
- 社会经济因素显著影响癌症患者的阿片类药物和大麻使用模式.
- 需要进一步的研究,以了解影响黑人患者癌症症状管理健康的社会决定因素.
- 解决社会经济障碍对于公平的瘤疼痛管理至关重要.
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
207
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
207
Analgesia and Pain Management
555
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
555
Opioid Analgesics: Synthetic and Semisynthetic Opioids
258
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
258
Drug Dependence
992
Medications are typically administered to achieve therapeutic effects. Some drugs can modify an individual's mood and perception, frequently resulting in various enjoyable experiences. However, this can result in drug dependency, a condition marked by continuous drug use despite potential negative consequences. Drug dependency primarily falls into two categories: psychological and physical dependence. Psychological dependence occurs when the pleasurable feelings induced by the drug...
992
Opioid Analgesics: Morphine and Other Natural Cogeners
206
Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
206
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K


